Objective: The etiology of plasma cell vulvitis (PCV) is debated. The authors aimed to test the hypothesis that PCV could be divided into 2 clinical phenotypes.
Methods: Patients with a clinico-pathological diagnosis of PCV and with available vulvar photos seen in a vulvar clinic were retrospectively studied. The cases of PCV were divided into 2 groups: non-lichen-associated (primary PCV) and lichen-associated (secondary PCV). The 2 groups were compared in terms of age, menopausal status, location of the PCV, and 12 histologic parameters (Fisher exact test, p < .05).
Results: Thirty-five patients (20 primary and 15 secondary PCV) were included. The 2 groups did not differ in terms of age (mean, 65; range, 50-85) or menopausal status. Primary PCV was located exclusively on the vestibule for 19/20 patients, whereas secondary PCV was extravestibular for 14 of 15 patients, either exclusively (2) or both extravestibular and vestibular (12). One patient with secondary PCV had solely vestibular involvement. Five histological features were observed significantly more often in case of secondary PCV: epidermal atrophy, parakeratosis, dermal and epidermal neutrophils, and dermal eosinophils.
Conclusions: Plasma cell vulvitis can be divided clinically into 2 phenotypes. Primary non-lichen-associated PCV is restricted to the vestibule and could be the vulvar counterpart of atrophic vaginitis. Secondary lichen-associated PCV is both extravestibular and vestibular, and its clinical and histological features should be looked for outside the PCV areas. This division of PCV into 2 clinical phenotypes could have therapeutic implications.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/LGT.0000000000000771 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of a Reduced PCV10 Dose Schedule on Pneumococcal Carriage in Vietnam.
N Engl J Med
November 2024
From the Department of Pediatric Infectious Diseases, Institute of Tropical Medicine (L.-M.Y., M. Toizumi, C.I., M. Takegata), the Department of Global Health, School of Tropical Medicine and Global Health (L.-M.Y., M. Toizumi), and Nagasaki University Graduate School of Biomedical Science (L.-M.Y.), Nagasaki University, Nagasaki, and the National Institute of Infectious Diseases, Tokyo (N.K.) - both in Japan; the Department of Bacteriology, National Institute of Hygiene and Epidemiology, Hanoi (H.A.T.N., L.H.H., D.-A.D.), and the Department of Bacteriology, Pasteur Institute, Nha Trang (L.T.L., H.T.D.) - both in Vietnam; the Department of Infectious Disease Epidemiology (B.J.Q., K.Z., K.M., S.F.) and the Centre for Mathematical Modelling of Infectious Diseases (B.J.Q., K.Z., S.F.), London School of Hygiene and Tropical Medicine, and the Institute for Infection and Immunity, St. George's University (J.H.) - both in London; the Department of Infection, Immunity, and Global Health, Murdoch Children's Research Institute (M.L.N., B.D.O., E.M.D., C.S., K.M.), and the Department of Paediatrics, University of Melbourne (C.S., K.M.), Melbourne, VIC, and the Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, VIC (C.S.) - all in Australia; and the Center for Global Health, Charité-Universitätmedizin Berlin, Berlin (S.F.).
Background: After pneumococcal disease and colonization have been controlled through vaccination campaigns, a reduced pneumococcal conjugate vaccine (PCV) schedule may be sufficient to sustain that control at reduced costs.
Methods: We investigated whether a single primary dose and booster dose (1p+1) of the 10-valent PCV (PCV10) would be noninferior to alternative dose schedules in sustaining control of carriage of pneumococcal serotypes included in the vaccine. In Nha Trang, Vietnam, an area in which PCV had not been used previously, a PCV10 catch-up campaign was conducted in which the vaccine was offered to children younger than 3 years of age, after which a cluster-randomized trial was conducted in which children received PCV10 at 2, 3, and 4 months of age (3p+0 group); at 2, 4, and 12 months of age (2p+1 group); at 2 and 12 months of age (1p+1 group); or at 12 months of age (0p+1 group).
Short-term fluctuation of intraocular pressure and influencing factors following intravitreal injection in patients with retinal vascular diseases.
Int J Ophthalmol
November 2024
Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Institute of Ophthalmology and Visual Sciences, Beijing 100730, China.
Aim: To investigate the patterns of short-term intraocular pressure (IOP) fluctuations and identify the contributing factors following intravitreal injection in patients with retinal vascular diseases.
Methods: Totally 81 patients were enrolled in this case control study. Eyes were categorized into 7 groups, including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), idiopathic choroidal neovascularization (CNV), proliferative diabetic retinopathy (PDR), diabetic macular edema (DME), macular edema secondary to branch (BVOME) and central (CVOME) retinal vein occlusion.
Incidence of severe and non-severe SARS-CoV-2 infections in children and adolescents: a population-based cohort study using six healthcare databases from Italy, Spain, and Norway.
Eur J Pediatr
November 2024
Julius Center for Health Sciences and Primary Care, Department of Data Science & Biostatistics, University Medical Center Utrecht, Utrecht, The Netherlands.
Unlabelled: We aim to estimate the incidence rates (IRs) of SARS-CoV-2 infections stratified by disease severity and comorbidities in pediatric population and to describe the COVID-19 vaccination coverage in children with and without comorbidities. A population-based cohort study was conducted in 6 electronic healthcare records databases from Italy, Spain, and Norway. The study lasted from 1 January 2020 to the latest databases' available data in each site, i.
View Article and Find Full Text PDFProton beam irradiation with anti-VEGF therapy for polypoidal choroidal vasculopathy: results of a 24-month, phase II randomized study.
Graefes Arch Clin Exp Ophthalmol
November 2024
Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, 83 Fenyang Road, Shanghai, China.
Purpose: To determine the efficacy and safety of proton beam irradiation (PBI) and anti-vascular endothelial growth factor (anti-VEGF) therapy for polypoidal choroidal vasculopathy (PCV)/ aneurysmal type 1 macular neovascularization (AT1).
Methods: The randomized clinical trial consisted of newly diagnosed active PCV/AT1 patients who were randomized 1:1 to treatment with three initial monthly intravitreal anti-VEGF agent (conbercept) injections with or without single 14 GyE radiation. Subsequent anti-VEGF therapy was given pro re nata.
[Characteristics of Depressed Individuals with Hypertension and/ or Diabetes Mellitus in Primary Health Care in Santiago de Chile].
Rev Med Chil
April 2024
Instituto Milenio para la Investigación en Depresión y Personalidad, Santiago, Chile.
Unlabelled: Eighty percent of depressed patients in Primary Health Care (PHC) have a comorbidity. It is essential to contribute local evidence on the characteristics of patients with physical and psychiatric comorbidities to better address clinical practice.
Aim: To characterize depressed patients from the cardiovascular program (PCV) of eight family health centers (CESFAM) in two communes of the Metropolitan Region.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!